医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

pembrolizumab

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: and KEYTRUDA enfortumab vedotin-ejfv EV-302 Trial PADCEV pembrolizumab

2023年09月22日

Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Evopoint Announces Clinical Trial Collaboration Agreement with in Advanced Solid Tumors pembrolizumab

2023年04月06日

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer pembrolizumab Seagen with KEYTRUDA

2022年12月20日

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験　 TimeLine: Early-Stage Triple-Negative Breast Cancer Including in High-Risk Merck’s KEYTRUDA pembrolizumab TNBC

2022年09月27日

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA pembrolizumab Qurient Announces Collaboration Agreement with

2022年09月15日

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Clinical Trial Investigating PADCEV enfortumab vedotin-ejfv pembrolizumab Seagen with KEYTRUDA

2022年09月12日

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: ESMO Genexine selected for Late-Breaking Oral Presentation of Phase pembrolizumab

2022年08月25日

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: as First-Line Treatment for Advanced Urothelial Cancer enfortumab vedotin-ejfv pembrolizumab Seagen and Astellas Announce Positive Topline Results For PADCEV with KEYTRUDA

2022年07月26日

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: KEYTRUDA lenvatinib pembrolizumab Plus LENVIMA

2022年02月25日

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy KEYTRUDA lenvatinib pembrolizumab Plus LENVIMA

2021年12月27日